Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience
| Autor: | Rufino Silva, Bora Eldem, Sibel Kadayifcilar, Rita Faria, P Kolar, N Feucht, A. Saeed, S Grisanti, Giovanni Staurenghi, L Rito, Philip G Hykin, António Campos, Stephen Beatty, L Maestroni, J. L. Olea, Sobha Sivaprasad, A. M. Barbosa |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
genetic structures Pegaptanib Visual Acuity Agudeza visual Cohort Studies 03 medical and health sciences Macular Degeneration 0302 clinical medicine Pan european Age related Ophthalmology medicine Pegaptanib Sodium Humans 030212 general & internal medicine Retrospective Studies business.industry Vascular Endothelial Growth Factors Macular degeneration Aptamers Nucleotide medicine.disease eye diseases Choroidal Neovascularization 3. Good health Intravitreal Injections 030221 ophthalmology & optometry Optometry sense organs business medicine.drug |
| Zdroj: | Eye (London, England). 24(5) |
| ISSN: | 1476-5454 |
| Popis: | To evaluate visual outcomes in patients with neovascular age-related macular degeneration (NV-AMD) who were treated with pegaptanib sodium in European clinical ophthalmology practices.Thirteen centres in eight European countries participated in this retrospective study. Medical records for patients with any angiographic subtype of subfoveal choroidal neovascularisation secondary to NV-AMD with visual acuities (study eye) of 20/40-20/320 treated with 0.3 mg pegaptanib as first-line treatment and with at least 24 weeks of follow-up were identified. Anonymised data reflecting at least 24 and up to 54 weeks of follow-up were recorded. Primary end points were visual acuity outcomes at weeks 24 and 54 compared with those reported at week 54 in the vascular endothelial growth factor (VEGF) Inhibition Study in Ocular Neovascularisation (VISION) trial.In all, 253 patients were followed for at least 24 weeks; 62 patients completed 54 weeks of follow-up. A mean of 4.4 (SD, 1.8) pegaptanib injections were administered through 24 weeks. Compared with the VISION trial, the European experience showed that90% of patients in the current cohort lost15 letters from baseline at both time points compared with 70% in the VISION trial at 54 weeks. Pegaptanib was well tolerated with no reported cases of endophthalmitis, traumatic cataract, or iatrogenic retinal detachment.Pegaptanib was found to stabilise vision in a greater percentage of patients and produced greater overall visual improvement in this group of treatment-naive patients with NV-AMD compared with outcomes reported in the VISION trial; however, interpretation of these results should be tempered given the differences in design between this retrospective study and the prospective controlled trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|